Bosch FX, Lorincz A, Muñoz N, Meijer CJLM, Shah KV. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol. 2002;55:244–65.
Article
CAS
PubMed
PubMed Central
Google Scholar
Gillison ML, Chaturvedi AK, Lowy DR. HPV prophylactic vaccines and the potential prevention of noncervical cancers in both men and women. Cancer. 2008;113:3036–46.
Article
PubMed
Google Scholar
Grulich AE, Jin F, Conway EL, Stein AN, Hocking J. Cancers attributable to human papillomavirus infection. Sex Health. 2010;7:244–52.
Article
PubMed
Google Scholar
Dunne EF, Markowitz LE. Genital human papillomavirus infection. Clin Infect Dis. 2006;43:624–9.
Article
PubMed
Google Scholar
Deleré Y, Wichmann O, Klug SJ, van der Sande M, Terhardt M, Zepp F, Harder T. The efficacy and duration of vaccine protection against human papillomavirus: a systematic review and meta-analysis. Dtsch Arztebl Int. 2014;111:584–91.
PubMed
PubMed Central
Google Scholar
Kash N, Lee MA, Kollipara R, Downing C, Guidry J, Tyring SK. Safety and efficacy data on vaccines and immunization to human papillomavirus. J Clin Med. 2015;4:614–33.
Article
PubMed
PubMed Central
Google Scholar
Lu B, Kumar A, Castellsagué X, Giuliano AR. Efficacy and safety of prophylactic vaccines against cervical HPV infection and diseases among women: a systematic review & meta-analysis. BMC Infect Dis. 2011;11:13.
Article
PubMed
PubMed Central
Google Scholar
Muñoz N, Bosch FX, Castellsagué X, Díaz M, de Sanjose S, Hammouda D, Shah KV, Meijer CJ. Against which human papillomavirus types shall we vaccinate and screen? The international perspective. Int J Cancer. 2004;111:278–85.
Article
PubMed
Google Scholar
Greer CE, Wheeler CM, Ladner MB, Beutner K, Coyne MY, Liang H, Langenberg A, Yen TS, Ralston R. Human papillomavirus (HPV) type distribution and serological response to HPV type 6 virus-like particles in patients with genital warts. J Clin Microbiol. 1995;33:2058–63.
CAS
PubMed
PubMed Central
Google Scholar
Ständige Impfkommission. Empfehlungen der Ständigen Impfkommission (STIKO) am Robert Koch-Institut/Stand: August 2014. Epidemiol Bull. 2014;34(2014):305–40.
Google Scholar
Ständige Impfkommission. Wissenschaftliche Begründung für die Änderung der Empfehlung zur Impfung gegen humane Papillomviren. Epidemiol Bull. 2014;35(2014):343–7.
Google Scholar
Horn J, Damm O, Kretzschmar MEE, Deleré Y, Wichmann O, Kaufmann AM, Garbe E, Krämer A, Greiner W, Mikolajczyk RT. Estimating the long-term effects of HPV vaccination in Germany. Vaccine. 2013;31:2372–80.
Article
CAS
PubMed
Google Scholar
Choi YH, Jit M, Gay N, Cox A, Garnett GP, Edmunds WJ. Transmission dynamic modelling of the impact of human papillomavirus vaccination in the United Kingdom. Vaccine. 2010;28:4091–102.
Article
PubMed
Google Scholar
Elbasha EH, Dasbach EJ, Insinga RP. Model for assessing human papillomavirus vaccination strategies. Emerg Infect Dis. 2007;13:28–41.
Article
PubMed
PubMed Central
Google Scholar
Zechmeister I, de Blasio BF, Garnett G, Neilson AR, Siebert U. Cost-effectiveness analysis of human papillomavirus-vaccination programs to prevent cervical cancer in Austria. Vaccine. 2009;27:5133–41.
Article
PubMed
Google Scholar
Canfell K, Barnabas R, Patnick J, Beral V. The predicted effect of changes in cervical screening practice in the UK: results from a modelling study. Br J Cancer. 2004;91:530–6.
Article
CAS
PubMed
PubMed Central
Google Scholar
Elbasha EH, Dasbach EJ, Insinga RP. A multi-type HPV transmission model. Bull Math Biol. 2008;70:2126–76.
Article
PubMed
Google Scholar
Kohli M, Ferko N, Martin A, Franco EL, Jenkins D, Gallivan S, Sherlaw-Johnson C, Drummond M. Estimating the long-term impact of a prophylactic human papillomavirus 16/18 vaccine on the burden of cervical cancer in the UK. Br J Cancer. 2007;96:143–50.
Article
CAS
PubMed
Google Scholar
Schneider A, Hammerschmidt T, Schwarz TF, Rogoza RM, Ferko N, Siebert U. Long-term public health impact of vaccination against cervical cancer in Germany. Geburtshilfe Frauenheilkd. 2007;67:850–8.
Article
Google Scholar
Sroczynski G, Schnell-Inderst P, Mühlberger N, Lang K, Aidelsburger P, Wasem J, Mittendorf T, Engel J, Hillemanns P, Petry K, Krämer A, Siebert U. Entscheidungsanalytische Modellierung zur Evaluation der Langzeit-Effektivität und Kosten-Effektivität des Einsatzes der HPV-DNA-Diagnostik im Rahmen der Zervixkarzinomfrüherkennung in Deutschland. Köln: Deutsches Institut für Medizinische Dokumentation und Information; 2010.
Google Scholar
Mikolajczyk RT, Horn J, Damm O, Kaufmann AM, Kretzschmar MEE. Epidemiological study of anti-HPV-16/18 seropositivity and subsequent risk of HPV-16 and -18 infections. J Natl Cancer Inst. 2012;104:163.
Article
PubMed
Google Scholar
Carter JJ, Koutsky LA, Hughes JP, Lee SK, Kuypers J, Kiviat N, Galloway DA. Comparison of human papillomavirus types 16, 18, and 6 capsid antibody responses following incident infection. J Infect Dis. 2000;181:1911–9.
Article
CAS
PubMed
Google Scholar
Safaeian M, Porras C, Schiffman M, Rodriguez AC, Wacholder S, Gonzalez P, Quint W, van Doorn L, Sherman ME, Xhenseval V, Herrero R, Hildesheim A. Epidemiological study of anti-HPV16/18 seropositivity and subsequent risk of HPV16 and -18 infections. J Natl Cancer Inst. 2010;102:1653–62.
Article
CAS
PubMed
PubMed Central
Google Scholar
Insinga RP, Dasbach EJ, Elbasha EH. Epidemiologic natural history and clinical management of human papillomavirus (HPV) disease: a critical and systematic review of the literature in the development of an HPV dynamic transmission model. BMC Infect Dis. 2009;9:119.
Article
PubMed
PubMed Central
Google Scholar
Kerek-Bodden H, Altenhofen L, Brenner G. Durchführung einer versichertenbezogenen Untersuchung zur Inanspruchnahme der Früherkennung auf Zervixkarzinom in den Jahren 2002, 2003 und 2004 auf der Basis von Abrechnungsdaten. Berlin: Zentralinstitut für die kassenärztliche Versorgung in der Bundesrepublik Deutschland; 2009.
Google Scholar
Robert Koch-Institut. Gesundheit in Deutschland. Berlin: Robert Koch-Institut; 2006.
Google Scholar
Deleré Y, Böhmer MM, Walter D, Wichmann O. HPV vaccination coverage among women aged 18–20 years in Germany three years after recommendation of HPV vaccination for adolescent girls: results from a cross-sectional survey. Hum Vaccines Immunother. 2013;9:1706–11.
Article
Google Scholar
Poethko-Müller C, Buttmann-Schwelger N, KiGGS Study Group. Impfstatus und Determinanten der Impfung gegen humane Papillomviren (HPV) bei Mädchen in Deutschland. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2014;57:869–77.
Article
PubMed
Google Scholar
Remschmidt C, Fesenfeld M, Kaufmann AM, Deleré Y. Sexual behavior and factors associated with young age at first intercourse and HPV vaccine uptake among young women in Germany: implications for HPV vaccination policies. BMC Public Health. 2014;14:1248.
Article
PubMed
PubMed Central
Google Scholar
Rieck T, Feig M, Deleré Y, Wichmann O. Utilization of administrative data to assess the association of an adolescent health check-up with human papillomavirus vaccine uptake in Germany. Vaccine. 2014;32:5564–9.
Article
PubMed
Google Scholar
Roggendorf H. Erste Erfahrungen zur Akzeptanz der HPV-Impfung. Monatsschr Kinderheilkd. 2009;157:982–5.
Article
Google Scholar
Stöcker P, Dehnert M, Schuster M, Wichmann O, Deleré Y. Human papillomavirus vaccine uptake, knowledge and attitude among 10th grade students in Berlin, Germany, 2010. Hum Vaccines Immunother. 2013;9:74–82.
Article
Google Scholar
de Vincenzo R, Conte C, Ricci C, Scambia G, Capelli G. Long-term efficacy and safety of human papillomavirus vaccination. Int J Womens Health. 2014;6:999–1010.
Article
PubMed
PubMed Central
Google Scholar
David M, van Herck K, Hardt K, Tibaldi F, Dubin G, Descamps D, van Damme P. Long-term persistence of anti-HPV-16 and -18 antibodies induced by vaccination with the AS04-adjuvanted cervical cancer vaccine: modeling of sustained antibody responses. Gynecol Oncol. 2009;115:S1–6.
Article
CAS
PubMed
Google Scholar
Fraser C, Tomassini JE, Xi L, Golm G, Watson M, Giuliano AR, Barr E, Ault KA. Modeling the long-term antibody response of a human papillomavirus (HPV) virus-like particle (VLP) type 16 prophylactic vaccine. Vaccine. 2007;25:4324–33.
Article
CAS
PubMed
Google Scholar
Beckmann MW, Mehlkorn G, Thiel F, Breuel C, Fasching PA, Ackermann S. Therapiefortschritte beim primären Zervixkarzinom. Dtsch Arztebl. 2005;102:A979–86.
Google Scholar
Dannecker C, Hantschmann P, Friese K. Stadienbezogene Therapie des Zervixkarzinoms. Gynäkologe. 2008;41:349.
Article
Google Scholar
Deutsche Krebsgesellschaft, Deutsche Gesellschaft für Gynäkologie und Geburtshilfe, Arbeitsgemeinschaft Gynäkologische Onkologie. Diagnostik und Therapie des Zervixkarzinoms, AWMF 032/033 (S2k). Berlin: Deutsche Gesellschaft für Gynäkologie und Geburtshilfe; 2008.
Hillemanns P. Manual Zervixkarzinom. 3rd ed. München: Tumorzentrum München und W. Zuckschwerdt Verlag GmbH; 2004.
Google Scholar
LAUER-TAXE. LAUER-FISCHER GmbH. http://www2.lauer-fischer.de. Accessed 17 Sept 2012.
Petry KU, Breugelmans JG, Bénard S, Lamure E, Littlewood KJ, Hillemanns P. Cost of screening and treatment of cervical dyskaryosis in Germany. Eur J Gynaecol Oncol. 2008;29:345–9.
CAS
PubMed
Google Scholar
Hillemanns P, Breugelmans JG, Gieseking F, Bénard S, Lamure E, Littlewood KJ, Petry KU. Estimation of the incidence of genital warts and the cost of illness in Germany: a cross-sectional study. BMC Infect Dis. 2008;8:76.
Article
PubMed
PubMed Central
Google Scholar
Krankheitsartenstatistik (Versicherte der Allgemeinen Ortskrankenkassen). AOK-Bundesverband. 2008. http://www.gbe-bund.de. Accessed 17 Sept 2012.
Bundesagentur für Arbeit. Arbeitsmarkt 2009. Nürnberg: Bundesagentur für Arbeit; 2010.
Google Scholar
Statistisches Bundesamt. Deutsche Wirtschaft 2010. Wiesbaden: Statistisches Bundesamt; 2011.
Google Scholar
Brisson M, Van de Velde N, de Wals P, Boily M. The potential cost-effectiveness of prophylactic human papillomavirus vaccines in Canada. Vaccine. 2007;25:5399–408.
Article
PubMed
Google Scholar
Insinga RP, Glass AG, Myers ER, Rush BB. Abnormal outcomes following cervical cancer screening: event duration and health utility loss. Med Decis Making. 2007;27:414–22.
Article
PubMed
Google Scholar
Institute of Medicine (U.S.). Commitee to Study Priorities for Vaccine Development. Vaccines for the 21st century: a tool for decisionmaking. Washington, D.C.: National Academy Press; 2000.
Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Allgemeine Methoden, Version 4.2. Köln: Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen; 2015.
von der Schulenburg JMG, Greiner W, Jost F, Klusen N, Kubin M, Leidl R, Mittendorf T, Rebscher H, Schoeffski O, Vauth C, Volmer T, Wahler S, Wasem J, Weber C. German recommendations on health economic evaluation: third and updated version of the Hanover consensus. Value Health. 2008;11:539–44.
Article
Google Scholar
Damm O, Ultsch B. Health economic evaluation of vaccines. Gesundh ökon Qual Manag. 2015;20:163–72.
Article
Google Scholar
Dobson SRM, McNeil S, Dionne M, Dawar M, Ogilvie G, Krajden M, Sauvageau C, Scheifele DW, Kollmann TR, Halperin SA, Langley JM, Bettinger JA, Singer J, Money D, Miller D, Naus M, Marra F, Young E. Immunogenicity of 2 doses of HPV vaccine in younger adolescents vs 3 doses in young women: a randomized clinical trial. JAMA. 2013;309:1793–802.
Article
CAS
PubMed
Google Scholar
Kreimer AR, Struyf F, Rosario-Raymundo Del, Rowena Maria, Hildesheim A, Skinner SR, Wacholder S, Garland SM, Herrero R, David M, Wheeler CM, González P, Jiménez S, Lowy DR, Pinto LA, Porras C, Rodriguez AC, Safaeian M, Schiffman M, Schiller JT, Schussler J, Sherman ME, Bosch FX, Castellsague X, Chatterjee A, Chow S, Descamps D, Diaz-Mitoma F, Dubin G, Germar MJ, Harper DM, et al. Efficacy of fewer than three doses of an HPV-16/18 AS04-adjuvanted vaccine: combined analysis of data from the Costa Rica vaccine and PATRICIA trials. Lancet Oncol. 2015;16:775–86.
Article
CAS
PubMed
PubMed Central
Google Scholar
Romanowski B, Schwarz TF, Ferguson LM, Ferguson M, Peters K, Dionne M, Schulze K, Ramjattan B, Hillemanns P, Behre U, Suryakiran P, Thomas F, Struyf F. Immune response to the HPV-16/18 AS04-adjuvanted vaccine administered as a 2-dose or 3-dose schedule up to 4 years after vaccination: results from a randomized study. Hum Vaccines Immunother. 2014;10:1155–65.
Article
Google Scholar
Forhan SE, Gottlieb SL, Sternberg MR, Xu F, Datta SD, McQuillan GM, Berman SM, Markowitz LE. Prevalence of sexually transmitted infections among female adolescents aged 14 to 19 in the United States. Pediatrics. 2009;124:1505–12.
Article
PubMed
Google Scholar
Iftner T, Eberle S, Iftner A, Holz B, Banik N, Quint W, Straube A. Prevalence of low-risk and high-risk types of human papillomavirus and other risk factors for HPV infection in Germany within different age groups in women up to 30 years of age: an epidemiological observational study. J Med Virol. 2010;82:1928–39.
Article
PubMed
Google Scholar
Klug SJ, Hukelmann M, Hollwitz B, Düzenli N, Schopp B, Petry K, Iftner T. Prevalence of human papillomavirus types in women screened by cytology in Germany. J Med Virol. 2007;79:616–25.
Article
PubMed
Google Scholar
de Sanjosé S, Diaz M, Castellsagué X, Clifford G, Bruni L, Muñoz N, Bosch FX. Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis. Lancet Infect Dis. 2007;7:453–9.
Article
PubMed
Google Scholar
Schneider A, Hoyer H, Lotz B, Leistritza S, Kühne-Heid R, Nindl I, Müller B, Haerting J, Dürst M. Screening for high-grade cervical intra-epithelial neoplasia and cancer by testing for high-risk HPV, routine cytology or colposcopy. Int J Cancer. 2000;89:529–34.
Article
CAS
PubMed
Google Scholar
Peto J, Gilham C, Deacon J, Taylor C, Evans C, Binns W, Haywood M, Elanko N, Coleman D, Yule R, Desai M. Cervical HPV infection and neoplasia in a large population-based prospective study: the Manchester cohort. Br J Cancer. 2004;91:942–53.
CAS
PubMed
PubMed Central
Google Scholar
GEKID-Atlas. Gesellschaft der epidemiologischen Krebsregister in Deutschland. http://www.gekid.de. Accessed 17 Sept 2012.
Castellsagué X, de Sanjose S, Aguado T, Louie KS, Bruni L, Muñoz N, Diaz M, Irwin K, Gacic M, Beauvais O, Albero G, Ferrer E, Byrne S, Bosch FX. HPV and cervical cancer in the 2007 report. Vaccine. 2007;25(Suppl 3):C1–230.
Google Scholar
Clifford GM, Gallus S, Herrero R, Muñoz N, Snijders PJF, Vaccarella S, Anh PTH, Ferreccio C, Hieu NT, Matos E, Molano M, Rajkumar R, Ronco G, de Sanjosé S, Shin HR, Sukvirach S, Thomas JO, Tunsakul S, Meijer CJLM, Franceschi S. Worldwide distribution of human papillomavirus types in cytologically normal women in the International Agency for Research on Cancer HPV prevalence surveys: a pooled analysis. Lancet. 2005;366:991–8.
Article
CAS
PubMed
Google Scholar
Clifford GM, Rana RK, Franceschi S, Smith JS, Gough G, Pimenta JM. Human papillomavirus genotype distribution in low-grade cervical lesions: comparison by geographic region and with cervical cancer. Cancer Epidemiol Biomark Prev. 2005;14:1157–64.
Article
Google Scholar
Smith JS, Lindsay L, Hoots B, Keys J, Franceschi S, Winer R, Clifford GM. Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. Int J Cancer. 2007;121:621–32.
Article
CAS
PubMed
Google Scholar
Kotsopoulos N, Connolly MP, Remy V. Quantifying the broader economic consequences of quadrivalent human papillomavirus (HPV) vaccination in Germany applying a government perspective framework. Health Econ Rev. 2015;5:54.
Article
PubMed
Google Scholar
Schobert D, Remy V, Schoeffski O. Cost-effectiveness of vaccination with a quadrivalent HPV vaccine in Germany using a dynamic transmission model. Health Econ Rev. 2012;2:19.
Article
PubMed
PubMed Central
Google Scholar
Soergel P, Makowski L, Schippert C, Staboulidou I, Hille U, Hillemanns P. The cost efficiency of HPV vaccines is significantly underestimated due to omission of conisation-associated prematurity with neonatal mortality and morbidity. Hum Vaccines Immunother. 2012;8:243–51.
Article
Google Scholar
Hillemanns P, Petry KU, Largeron N, McAllister R, Tolley K, Büsch K. Cost-effectiveness of a tetravalent human papillomavirus vaccine in Germany. J Public Health. 2009;17:77–86.
Article
Google Scholar
Zarnke KB, Levine MA, O’Brien BJ. Cost-benefit analyses in the health-care literature: don’t judge a study by its label. J Clin Epidemiol. 1997;50:813–22.
Article
CAS
PubMed
Google Scholar
Yahia MBBH, Jouin-Bortolotti A, Dervaux B. Extending the human papillomavirus vaccination programme to include males in high-income countries: a systematic review of the cost-effectiveness studies. Clin Drug Investig. 2015;35:471–85.
Article
Google Scholar
Kim JJ. Targeted human papillomavirus vaccination of men who have sex with men in the USA: a cost-effectiveness modelling analysis. Lancet Infect Dis. 2010;10:845–52.
Article
PubMed
PubMed Central
Google Scholar
Deshmukh AA, Chiao EY, Das P, Cantor SB. Clinical effectiveness and cost-effectiveness of quadrivalent human papillomavirus vaccination in HIV-negative men who have sex with men to prevent recurrent high-grade anal intraepithelial neoplasia. Vaccine. 2014;32:6941–7.
Article
PubMed
PubMed Central
Google Scholar
Lin A, Ong KJ, Hobbelen P, King E, Mesher D, Edmunds WJ, Sonnenberg P, Gilson R, Bains I, Choi YH, Tanton C, Soldan K, Jit M. Impact and cost-effectiveness of selective human papillomavirus vaccination of men who have sex with men. Clin Infect Dis. 2017;64:580–8.
PubMed
Google Scholar
Ultsch B, Damm O, Beutels P, Bilcke J, Brüggenjürgen B, Gerber-Grote A, Greiner W, Hanquet G, Hutubessy R, Jit M, Knol M, von Kries R, Kuhlmann A, Levy-Bruhl D, Perleth M, Postma M, Salo H, Siebert U, Wasem J, Wichmann O. Methods for health economic evaluation of vaccines and immunization decision frameworks: a consensus framework from a European vaccine economics community. Pharmacoeconomics. 2016;34:227–44.
Article
PubMed
Google Scholar
de Kok IMCM, Habbema JDF, van Rosmalen J, van Ballegooijen M. Would the effect of HPV vaccination on non-cervical HPV-positive cancers make the difference for its cost-effectiveness? Eur J Cancer. 2011;47:428–35.
Article
PubMed
Google Scholar
Olsen J, Jørgensen TR. Revisiting the cost-effectiveness of universal HPV-vaccination in Denmark accounting for all potentially vaccine preventable HPV-related diseases in males and females. Cost Eff Resour Alloc. 2015;13:4.
Article
PubMed
PubMed Central
Google Scholar
Canvin M, Sinka K, Hughes G, Mesher D. Decline in genital warts diagnoses among young women and young men since the introduction of the bivalent HPV (16/18) vaccination programme in England: an ecological analysis. Sex Transm Infect. 2016. doi:10.1136/sextrans-2016-052626.
PubMed
Google Scholar
Szarewski A, Skinner SR, Garland SM, Romanowski B, Schwarz TF, Apter D, Chow SN, Paavonen J, Del Rosario-Raymundo MR, Teixeira JC, De Carvalho NS, Castro-Sanchez M, Castellsagué X, Poppe WAJ, De Sutter P, Huh W, Chatterjee A, Tjalma WA, Ackerman RT, Martens M, Papp KA, Bajo-Arenas J, Harper DM, Torné A, David MP, Struyf F, Lehtinen M, Dubin G. Efficacy of the HPV-16/18 AS04-adjuvanted vaccine against low-risk HPV types (PATRICIA randomized trial): an unexpected observation. J Infect Dis. 2013;208:1391–6.
Article
CAS
PubMed
PubMed Central
Google Scholar
Luyten A, Buttmann-Schweiger N, Luyten K, Mauritz C, Reinecke-Lüthge A, Pietralla M, Meijer CJLM, Petry KU. Early detection of CIN3 and cervical cancer during long-term follow-up using HPV/Pap smear co-testing and risk-adapted follow-up in a locally organised screening programme. Int J Cancer. 2014;135:1408–16.
Article
CAS
PubMed
Google Scholar
Paavonen J, Naud P, Salmerón J, Wheeler CM, Chow S, Apter D, Kitchener H, Castellsague X, Teixeira JC, Skinner SR, Hedrick J, Jaisamrarn U, Limson G, Garland S, Szarewski A, Romanowski B, Aoki FY, Schwarz TF, Poppe WAJ, Bosch FX, Jenkins D, Hardt K, Zahaf T, Descamps D, Struyf F, Lehtinen M, Dubin G. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet. 2009;374:301–14.
Article
CAS
PubMed
Google Scholar
The FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med. 2007;356:1915–27.
Article
Google Scholar
Garland SM, Hernandez-Avila M, Wheeler CM, Perez G, Harper DM, Leodolter ST, Grace WK, Ferris DG, Steben M, Bryan J, Taddeo FJ, Railkar R, Esser MT, Sings HL, Nelson M, Boslego J, Sattler C, Barr E, Koutsky LA. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med. 2007;356:1928–43.
Article
CAS
PubMed
Google Scholar
Giuliano AR, Palefsky JM, Goldstone S, Moreira ED, Penny ME, Aranda C, Vardas E, Moi H, Jessen H, Hillman R, Chang Y, Ferris D, Rouleau D, Bryan J, Marshall JB, Vuocolo S, Barr E, Radley D, Haupt RM, Guris D. Efficacy of quadrivalent HPV vaccine against HPV Infection and disease in males. N Engl J Med. 2011;364:401–11.
Article
CAS
PubMed
PubMed Central
Google Scholar
Brown DR, Kjaer SK, Sigurdsson K, Iversen O, Hernandez-Avila M, Wheeler CM, Perez G, Koutsky LA, Tay EH, Garcia P, Ault KA, Garland SM, Leodolter S, Olsson S, Tang GWK, Ferris DG, Paavonen J, Steben M, Bosch FX, Dillner J, Joura EA, Kurman RJ, Majewski S, Muñoz N, Myers ER, Villa LL, Taddeo FJ, Roberts C, Tadesse A, Bryan J, et al. The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16–26 years. J Infect Dis. 2009;199:926–35.
Article
PubMed
Google Scholar
Szarewski A. HPV vaccine: cervarix. Expert Opin Biol Ther. 2010;10:477–87.
Article
CAS
PubMed
Google Scholar
Goldie SJ, Kohli M, Grima D, Weinstein MC, Wright TC, Bosch FX, Franco E. Projected clinical benefits and cost-effectiveness of a human papillomavirus 16/18 vaccine. J Natl Cancer Inst. 2004;96:604–15.
Article
PubMed
Google Scholar
Gold MR, Franks P, McCoy KI, Fryback DG. Toward consistency in cost-utility analyses: using national measures to create condition-specific values. Med Care. 1998;36:778–92.
Article
CAS
PubMed
Google Scholar
de Kok IMCM, van Ballegooijen M, Habbema JDF. Cost-effectiveness analysis of human papillomavirus vaccination in the Netherlands. J Natl Cancer Inst. 2009;101:1083–92.
Article
PubMed
Google Scholar